Purpose: To summarize the development, nomenclature, and rationale of the reported use of monoclonal antibodies (Mabs) in Graves Orbitopathy (GO) and to undertake a systematic review of the management of GO with Mabs. Methods: The Pubmed and Embase databases and the Federal Brazilian searching site (Periódicos-CAPES) were screened. The authors searched all the keywords “monoclonal antibodies,” “adalimumab,” “belimumab,” “infliximab,” “rituximab,” “teprotumumab,” and “tocilizumab” combined with the terms “Graves Orbitopathy,” “Graves eye disease” and “thyroid eye disease.” All the articles published in English, French, and Spanish from 2000 to May 2022 were screened. Only publications with quantitative data on the activity of orbitopathy, proptosis, or both were included. Results: Seventy-six articles of the 954 screened records met the inclusion criteria. Seven Mabs were described for treating GO. The three most reported Mabs were Rituximab, Tocilizumab, and Teprotumumab. Only eight randomized clinical trials compared the effect of these three Mabs and Belimumab with the effect of steroids or placebos. Adalimumab, Infliximab, and K1-70 only appeared in a few case series and case reports. Frequent mild-to-moderate and few major side effects occurred with the three most used Mabs. Relapse rates ranged from 7.4% for Tocilizumab to at least 29.4% for Teprotumumab. No randomized clinical trials compared Mabs head-to-head. Conclusion: Considering the lack of head-to-head comparisons between Mabs, the relapse rate, the possibility of severe collateral effects, and the cost of Mabs, it is not clear which Mab is the safest and most useful to treat GO.

Objective: To evaluate the correlation of flow and stopping time intraoperative loss of attachment factors as hypertension or hipocorreções of refractive errors after Lasik. Methods:The age ranged between 19 and 61 years (mean= 31.27 ± 9.99 (mean= 0.23 ± 0.69) and postoperative uncorrected 0.40-0 (x= 0.30 ± 0, 68). (mean= 0.545 ± 0.01), p = 0.762) between the flow and spherical equivalent (mean = -0.04 ± 0.38) in eyes operated. The minimal downtime during surgery was 02 seconds and maximum was 12 seconds (mean= 4.90 ± 3.47). Making a correlation (r = 0.08865, p = 0.411) p=0,424). No equivalente esférico pré e pós-operatório, notou-se uma óbvia diferença (p< 0,0001), no pré-operatório com média de -4,09 ± 2,83 e o pós com média de -0,04 ± 0,38. A mediana foi de -4,75 no pré e de 0 no pós-operatório. Sessenta e nove casos (78,3%) ficaram plano ± 0,25. A fluência mínima foi de 0,513 mJ/cm 2 e a máxima de 0,581 mJ/cm 2 com média de 0,545 ± 0,01, não se percebendo correlação (r= -0,03266; IC 95% -0,241 a 0,178; p= 0,762) entre a fluência e o equivalente esférico final (média= -0,04 ± 0,38) nos olhos operados. O tempo mínimo de parada transoperatória foi de dois segundos e o máximo de 12 segundos com média de 4,90 ± 3,47. Fazendo-se uma correlação (r= 0,08865; IC 95%= -0,123 a 0,293; p= 0,411) entre o equivalente esférico pós-operatório e o tempo de parada transoperatória, não se percebeu diferenças. Conclusão: Não houve correlação entre a fluência do laser e o tempo de parada transoperatória por perda de fixação, com hiper ou hipocorreções nas ametropias pós-Lasik. The Median= 0 logMAR for both time points (p= 0.424). For spherical equivalent before and after surgery, we found an obvious difference, with the pre (mean= -4.09 ± 2.83) and post (mean= -0.04 ± 0.38). The Median was -4.75 in the pre and zero postoperatively (p <0.0001). Sixty-nine cases (78.3%) were plan ± 0.25. Fluency minimum= 0.513 mJ/cm2 and maximum= 0.581 mJ/cm2Descritores (1) . Pallikaris was the first to promote the removal of corneal stromal tissue with excimer laser to correct refractive errors (2) . The use of excimer laser to correct myopia, hyperopia and astigmatism evolved in recent years, mainly due to the technological advancement of devices.Laser-assisted in situ keratomileusis (LASIK) is still the most widely used technique; it is a painless, safe, and accurate method for treating refractive errors with quick recovery (3)(4)(5) . By preserving epithelial integrity in the central region of the cornea, it promotes a milder wound healing reaction. The healing response triggered by the laser and the creation of a flap are important to the safety and efficacy of the procedure. However, it is a significantly complex event (6) . The literature reports great refractive stability from the 3 rd month after surgery (7)(8)(9) . However, do intraoperative factors such as daily variations in laser fluence and interruptions during laser application due to loss of fixation influence the refractive outcome?The aim of this study was to ev...